Sage Journals: Discover world-class research

Abstract

The thymidine salvage pathway enzymes thymidine kinase 1 (TK1) and thymidine phosphorylase (TP) compete for thymidine as a substrate and catalyze opposing synthetic and catabolic reactions that have been implicated in the control of proliferation and angiogenesis, respectively. We investigated the relationship between the expression of TK1 and TP as they relate to proliferation (Ki-67 labeling index) and angiogenesis (Chalkley count of CD31-stained blood vessels) in a series of 110 non-small-cell lung cancer (NSCLC) tumors from patients prospectively enrolled in an imaging trial. TK1 and TP exhibited similar patterns of immunohistochemical distribution, in that each was found in both the nucleus and the cytoplasm of tumor cells. Each enzyme exhibited a significant positive correlation between its levels of nuclear and cytoplasmic expression. A significant positive correlation between TK1 expression and the Ki-67 labeling index (r = 0.53, p<0.001) was observed. TP was significantly positively correlated with Chalkley scoring of CD31 staining in high vs low Chalkley scoring samples (mean TP staining of 115.8 vs 79.9 scoring units, p<0.001), respectively. We did not observe a substantial inverse correlation between the TP and TK1 expression levels in the nuclear compartment (r = −0.17, p=0.08). Tumor size was not found to be associated with TK1, TP, Ki-67, or Chalkley score. These findings provide additional evidence for the role of thymidine metabolism in the complex interaction of proliferation and angiogenesis in NSCLC.

Keywords

thymidine kinase 1 thymidine phosphorylase NSCLC angiogenesis proliferation

TUMOR GROWTH results from the net accumulation of tumor cells, with cell proliferation balanced by cell loss resulting from shedding, apoptosis, and non-apoptotic mechanisms, including necrosis and entosis (Landry et al. 1981; Cotter et al. 1990; Overholtzer et al. 2007). Angiogenesis is critical to sustaining this growth once the tumor reaches a diameter of 1 to 2 mm (Folkman 2003). One of the major focuses of cancer research in the past 20 years has been to define the interplay between tumor proliferation and angiogenesis.

Several lines of evidence suggest that thymidine occupies a central position in determining the relationship between proliferation and angiogenesis (Figure 1). Thymidine undergoes a series of phosphorylations to form thymidine triphosphate (dTTP), one of the four basic building blocks of DNA synthesis, whereas its catabolic metabolite is the immediate precursor to 2-deoxyribose (2-dR), a potent angiogenic stimulus (Haraguchi et al. 1994; Brown and Bicknell 1998; Uchimiya et al. 2002; Hotchkiss et al. 2003).

The enzymes controlling thymidine and thymidylate [or thymidine monophosphate (dTMP)] synthesis and catabolism are elevated in hematologic malignancies (Vertongen et al. 1984; Shiotani et al. 1989a,b), as well as in several solid tumors, relative to surrounding non-malignant tissue. Tumor-specific elevation of the expression of cytosolic thymidine kinase 1 (TK1), a key enzyme of the thymidine salvage pathway, has been documented in a variety of cancers including non-small-cell lung cancer (NSCLC) (Yusa et al. 1988; Maehara et al. 1990). TK1 catalyzes the critical initial phosphorylation of thymidine to thymidylate, providing the substrate for subsequent phosphorylations to provide dTTP for DNA synthesis and repair. Increased TK1 expression is often associated with increased expression of cell proliferation markers such as the Ki-67 antigen and proliferating cell nuclear antigen (Wu et al. 2000; Mao et al. 2002; Oudard et al. 2002).

Figure 1

Thymidine plays a central role in both proliferation and angio-genesis. TP, thymidine phosphorylase; TK1, thymidine kinase 1; dTMPK, thymidine monophosphate kinase; NDPK, nucleotide diphsophate kinase; dTTP, thymidine triphosphate; dTMP, thymidine monophosphate (thymidylate); 2-dR-1-P, 2-deoxyribose-1-phosphate. Unequal reversible reaction arrows indicate that thymidine catabolism is usually the energetically preferred direction of bidirectional TP catalysis.

Another thymidine salvage pathway enzyme, thymidine phosphorylase (TP, also known as platelet-derived endothelial cell growth factor), catalyzes the reversible catabolism of thymidine to form thymine and 2-deoxyribose-1-phosphate (2-dR-1-P), which undergoes rapid dephosphorylation (de Bruin et al. 2003) to form 2-dR, a potent angiogenic and anti-apoptotic chemical signal (Haraguchi et al. 1994; Brown and Bicknell 1998; Ikeda et al. 2002, 2006; Uchimiya et al. 2002; Hotchkiss et al. 2003). TP expression has also been shown to be elevated in a variety of tumors, relative to adjacent non-tumorous tissue (Moghaddam et al. 1995; O'Brien et al. 1995, 1996; Takebayashi et al. 1996a,b; Ikeguchi et al. 1999; Koide et al. 1999; Hirano et al. 2003; Morita et al. 2003; Passantino et al. 2005; Miyake et al. 2007), including NSCLC (Takebayashi et al. 1996a; Koukourakis et al. 1997, 1998; Volm et al. 1998; Aikawa et al. 1999; O'Byrne et al. 2000; Sato et al. 2003; Chujo et al. 2006), and is associated with increased microvessel density (MVD) in several tumor types (Matsuura et al. 1999; Giatromanolaki et al. 2002; Li et al. 2005; Yasuno et al. 2005).

The fact that proliferation-associated TK1 and angiogenesis-associated TP compete for the substrate thymidine and catalyze opposing reactions (synthesis vs catabolism) of the thymidine salvage pathway suggests that thymidine may occupy a central position in determining the relationship between proliferation and angiogenesis (Liekens et al. 2007). Although many studies have examined TK1 and TP expression or their enzyme activities in individual tumor samples in parallel, very few have looked for evidence of their coordinated regulation by testing for an association between their expressions (Fujiwaki et al. 2001).

The pro-angiogenic actions of TP, coupled with reports of the prognostic value of tumor TP levels in cancer patients, indicate that obtaining non-invasive, repeatable, quantitative measures of TP in human tumors would be useful in several ways, including identifying patients who may have a poorer prognosis, and assessing angiogenesis-related tumor growth potential, which may predict response to anti-angiogenic agents (Klecker and Collins 2001). Positron emission tomography (PET) is already ideally suited for quantitative and non-invasive measures of tumor proliferation using the specific tracer of cellular TK1 activity, 3'-deoxy-3'-[F-18]flourothymidine (Shields et al. 1998; Grierson and Shields 2000; Rasey et al. 2002; Vesselle et al. 2002). A PET radiotracer to quantify tumor TP levels will offer a novel tool for examining other essential features of tumor biology and would complement our ability to non-invasively assess tumor prognosis, angiogenesis, and response to certain chemotherapies. We previously developed the PET tracer 5'-deoxy-5'-[F-18]fluorothymidine as a potential marker of TP activity. However, uptake studies in cultured lung cancer cells revealed that this tracer was rapidly metabolized and leaked from cells into the medium (Grierson et al. 2007). Future efforts to develop and validate a PET radiotracer to image TP activity in human cancer patients will require a solid understanding of TP expression and its relation to tumor proliferation.

In a series of prospectively accrued and treated NSCLC patients undergoing primary surgical resection without neo-adjuvant or adjuvant treatment, we used immunohistochemical (IHC) methods to study the relationship between TK1 and TP expression. We used as correlates the Ki-67 score as an overall measure of tumor proliferation, and a Chalkley score of CD31 staining as an end-point measure of angiogenesis for these tumors.

Materials and Methods

Patient Population and Tumor Type

All subjects in the present IHC study are a subset of patients from a larger prospective study of fluorodeoxy-glucose PET imaging in NSCLC conducted under the approval of the University of Washington Human Subjects Division. Informed consent was obtained according to procedures approved by the Human Subjects Committee of the University of Washington. Two hundred and eight potentially resectable NSCLC patients were enrolled into the imaging trial, the results of which have been recently reported (Vesselle et al. 2007), and their management followed the standard NSCLC care algorithm previously described (Vesselle et al. 2004). In 110 of the 208 subjects, a primary tumor block was available for IHC analysis.

Immunohistochemistry

Four-micron sections of formalin-fixed, paraffin-embedded tissue were cut and placed on Superfrost Plus microscope slides (Fisher Scientific; Pittsburgh, PA). The tissue sections were deparaffinized and rehydrated through graded alcohols. Antigen retrieval was carried out with Tris/EDTA, pH 9.0, buffer in a tabletop autoclave. Endogenous peroxidase activity was blocked with 3% H₂O₂. In preliminary tests, each primary antibody was titered across a range of dilutions to determine the optimal concentration that produced strong specific staining with no background. The clone designation, vendor, dilution, and target protein specificity citation for the antibodies used are as follows: CD31 [JC70A; DAKO Corporation, Carpintera, CA, at 1:500 (Parums et al. 1990)]; Ki-67 [MIB-1; DAKO Corporation, at 1:500 (Key et al. 1993)]; TK1 [3B3.E11; QED Biosciences, Inc., San Diego, CA, at 1:500 (Tu et al. 2006) and http://www.abcam.com/index.html?pageconfig=reviews & intAbreviewID=11846&intAbID=988]; and TP [PGF.44C; Lab Vision Corporation, Fremont, CA, at 1:4000 (Fox et al. 1995b)]. The appropriate antibody was applied to each slide. The slides were washed and ImmPRESS (Vector Laboratories; Burlingame, CA), an anti-mouse IgG polymerized reporter enzyme, was applied to each tissue. Color development was accomplished by incubation in diaminobenzidine (DAKO Corporation). The slides were counterstained in hematoxylin (DAKO Corporation), dehydrated through graded alcohols, cleared in xylene, and coverslipped with permanent mounting media. A slide lacking the addition of the primary antibody was used as a negative control. For each of the four antibodies used in this study, these control slides demonstrated a complete absence of peroxidase staining (data not shown). Each stained slide was read independently by two experienced investigators (JKM, JSB). In the event of a discrepancy in scoring, both investigators examined the slide simultaneously on a dual-head teaching microscope and arrived at a consensus score.

Assessment of TK1 and TP Expression. Preliminary examination of TK1 and TP staining revealed a marked heterogeneity within sections, which has been widely reported for many immunohistochemical markers in NSCLC (Gatter et al. 1985; Dunnill and Gatter 1986) and which invalidates assessment of expression using a simple intensity score for each slide. For this reason, TK1 expression and TP expression were assessed using a graded semi-quantitative scoring method. Staining intensity was scored as 0, 1+, 2+, or 3+. For each of these four staining intensity scores, the percentage of cells staining at that respective intensity score was determined and multiplied by the intensity score to yield an intensity percentage score. The final TK1 and TP staining scores used in analyses were calculated from the sum of the four intensity percentage scores. Thus, the staining score had a minimum value of 0 (no staining) and a maximum of 300 (100% of cells with 3+ staining intensity). TK1 expression and TP expression were evaluated in both the nucleus and the cytoplasm of the tumor cells and were designated as TK1_nuc or TP_nuc and TK1_cyt or TP_cyt, respectively (Table 1). Because of the potential for the signal from one cellular compartment to influence the scoring of the other compartment (e.g., cytoplasmic staining influencing the scoring of the nuclear staining), a subgroup of slides was scored again to determine whether bias was present. In a subset of 30 cases, cytoplasmic or nuclear staining was re-read independently and compared with the scores initially obtained. We observed a strong correlation in staining scores in the original and re-read samples (r = 0.96 for TP_nuc, r = 0.83 for TP_cyt).

Table 1

Mean immunohistochemical scores

	Mean ± SD	No. (%)
TP_nuc staining score	81.5 ± 49.8
TP_cyt staining score	96.6 ± 47.0
TK1_nuc staining score	58.2 ± 35.8
TK1_cyt staining score	73.8 ± 43.4
Ki-67 labeling index (% positive)	49.0 ± 24.9
CD31 Chalkley score ∗
≤6		53 (51%)
>6		50 (49%)

^∗Only 103 NSCLC patients had CD31 results.

TP, thymidine phosphorylase; TK1, thymidine kinase 1.

Chalkley Scoring of CD 31 Staining. Angiogenesis was assessed by the Chalkley counting method for determining the MVD index as described by Fox with some modifications (Fox et al. 1994, 1995a). The Chalkley count is a measure of the relative area occupied by the stained blood vessels as opposed to the density of vessels within a high-power field (i.e., MVD). Tumors were scanned under low power (10×) to determine the three areas with the highest vascularity (“hotspots”). Areas of adjacent normal lung tissue, and areas of necrosis or sclerosis, were not included. The Chalkley graticule (Chalkley 1943) is a disk imprinted with 25 randomly placed dots. Under high power (200×), the Chalkley graticule was rotated and oriented so that the maximum number of dots contacted the CD31-positive blood vessels. Any stained single endothelial cell or endothelial cell cluster with or without a vessel lumen was counted. The Chalkley score was determined as the mean of the three counts (Table 1). For the purpose of analyses, the Chalkley score was dichotomized into two levels, low and high, which correspond to values below and above the median Chalkley score of 6.

Ki-67 Labeling Index Determination. The Ki-67 labeling index was determined by estimating the percentage of tumor cells stained with the MIB-1 antibody (Table 1).

Statistical Analysis

Because the staining markers were not necessarily normally distributed, or were ordinal in nature, non-parametric Spearman's rank correlation coefficients were used to determine the degree of correlation between measurements of staining markers (TP, TK1, Ki-67, and CD31). Similarly, non-parametric Wilcoxon rank-sum tests were used to assess differences in levels of staining markers between groups, and paired Wilcoxon signed-rank tests were utilized to compare levels of staining markers within individuals. A two-sided 0.05 test level determined statistical significance for all analyses. All analyses were conducted using SAS version 9.1 (SAS Institute, Inc.; Cary, NC).

Results

The baseline characteristics of the study subjects are summarized in Table 2. The mean age of the 110 NSCLC cases was 65 years, approximately one third were female (37%), and most were caucasian (89%). All but four patients reported a history of smoking, with 72% reporting at least 40 pack-years of smoking at the time of enrollment in the imaging trial. The majority of these NSCLC cases had surgical stage I (58%) or II (25%) disease, and more than half (60%) had tumors <3 cm in size. By histology, 40% of tumors were adenocarcinomas, 35% were squamous cell carcinomas, 14% were large-cell carcinomas, 5% were bronchoalveolar carcinomas, and the remaining 6% were of mixed or unspecified histology. Greater than half (57%) of the tumors were poorly differentiated.

Nuclear TP vs Cytoplasmic TP

Figure 2 illustrates the well-known heterogeneous nature of NSCLC tumors, both with regard to the staining of specific markers as well as overall morphology (Gatter et al. 1985; Dunnill and Gatter 1986). TP expression was evaluated in both the nuclear and cytoplasmic compartments of the tumor cells (Figures 2 and 3) to determine whether there were any differences in expression between the two compartments. TP was localized in both the nuclear and cytoplasmic compartments of the tumor cells. The TP_cyt staining score was, on average, significantly greater than the TP_nuc staining score (p<0.001, paired Wilcoxon signed-rank test) and was closely correlated with the TP_nuc staining score (r = 0.85, p<0.001, Spearman's correlation coefficient). Within each histological subtype (adenocarcinoma vs squamous cell carcinoma), similar results were observed when comparing TP_cyt and TP_nuc staining scores (data not shown).

Table 2

Baseline demographic and tumor characteristics of 110 NSCLC patients

	No. (%)
Age at enrollment (mean 65.2 ± 8.9 years)
<50 years	4 (4)
50–59 years	29 (26)
60–69 years	40 (36)
≥ 70 years	37 (34)
Female gender	41 (37)
Caucasian race	98 (89)
Smoking pack-years
0 (Non-smoker)	4 (4)
1–39	24 (22)
40+	79 (72)
Smoker, but amount unknown	3 (3)
Stage
I	64 (58)
II	28 (25)
III	17 (15)
IV	1 (1)
Tumor size (mean 2.9 ± 1.4 cm)
<3 cm	66 (60)
3–5 cm	35 (32)
≥5 cm	9 (8)
Histology
Adenocarcinoma (non-BAC)	44 (40)
Squamous	38 (35)
Large-cell	15 (14)
Bronchoalveolar cell (BAC)	6 (5)
NSCLC, NOS/mixed	7 (6)
Differentiation
Well	7 (6)
Moderate	40 (36)
Poor	63 (57)

NSCLC, non-small-cell lung cancer; BAC, bronchoalveolar carcinoma; NOS, not otherwise specified.

Figure 2

Representative examples of immunohistochemical staining. (A) TP-low composite score. (B) TP-high composite score. (C) TK1-low composite score. (D) TK1-high composite score. (E) CD31 staining. (F) Ki-67 staining. Bar = 50 μm.

Nuclear TK1 vs Cytoplasmic TK1

TK1 expression was assessed in both the nucleus and the cytoplasm of the tumor cells to determine whether differences in expression exist between the two compartments (Figures 2 and 4). Localization of TK1 was observed in both the nuclear and cytoplasmic compartments of the tumor cells, as previously noted, using immunohistochemistry, immunofluorescence, and enzyme assay methods (Johansson et al. 1997; veer Reddy and Pardee 1980; Kuroiwa et al. 2001; Cui et al. 2004). The TK1_cyt staining score was, on average, significantly greater than the TK1_nuc staining score (p< 0.001, paired Wilcoxon signed-rank test) and we observed a close correlation between the TK1 staining scores in the nuclear and cytoplasmic compartments (r = 0.78, p< 0.001, Spearman's correlation coefficient). We also observed similar results when comparing the two staining scores separately within each histological subtype (data not shown).

Given the high degree of correlation between the nuclear and cytoplasmic expression of both TK1 and TP, in the majority of analyses, we will present cytoplasmic expression of TK1 and TP only, except when differences were observed.

Relationship Between TK1 Staining and Ki-67 Labeling Index

In contrast to TK1 and TP, Ki-67 was found to be exclusively localized in the nuclear compartment (Figure 2). The TK1_cyt staining score was significantly correlated with the Ki-67 labeling index (r = 0.53, p<0.001, Spearman's correlation coefficient), as shown in Figure 5, and consistent with the role of TK1 in the eventual synthesis of dTTP as well as a previous report of TK1 and Ki-67 staining in NSCLC (Mao et al. 2005). When considering staining within each histological subtype (adenocarcinoma or squamous cell carcinoma), similar results were observed (data not shown).

Figures 3–5

Figure 3

Nuclear TP staining vs cytoplasmic TP staining. Cytoplasmic TP staining was strongly correlated with (r = 0.85, p< 0.001) and significantly greater than (p<0.001) nuclear TP staining.

Figure 4

Nuclear TK1 staining vs cytoplasmic TK1 staining. Cytoplasmic TK1 staining was strongly correlated with (= 0.78, p< 0.001) and significantly greater than (p<0.001) nuclear TK1 staining.

Figure 5

Cytoplasmic TK1 staining vs Ki-67 labeling index. Cytoplasmic TK1 staining was significantly correlated with the Ki-67 labeling index (r = 0.53, p<0.001).

Relationship Between TP Staining and Chalkley Score

TP has been shown to have angiogenic activity, believed to be due to one of its end products, 2-dR-1-P. The Chalkley score based on CD31 staining is representative of the relative area occupied by nascent blood vessels. The median Chalkley score value (6) was used as the cut-off point for dichotomizing the Chalkley score into low and high categories. The mean TP_cyt staining score was significantly greater for high Chalkley scores (>6) compared with low Chalkley scores (≤6) (mean 115.8 vs 79.9, p<0.001, Wilcoxon rank-sum test), as seen in Figure 6. Similar results were observed when considering these scores within each histological subtype (adenocarcinoma or squamous cell carcinoma) (data not shown). In addition to being expressed by blood vessels, CD31 was also expressed on macrophages and plasma cells. Because these cell types are easily distinguished from blood vessels, their staining did not compromise our analysis.

TK1 Staining vs TP Staining

Given that TK1 and TP share a common substrate, and that TP is catabolic whereas TK1 is synthetic, it might be expected that their expression would be inversely related, as has been reported in hematologic malignancies (Shiotani et al. 1989a,b). We found that the TP_cyt staining score was on average significantly greater than the TK1_cyt staining score (Table 1, p=0.0002, paired Wilcoxon signed-rank test), but there was no significant correlation (inverse or otherwise) between the scores (r = 0.04, p=0.64; Spearman's correlation coefficient, data not shown). Similar to what was observed in the cytoplasm, nuclear TP staining was greater than nuclear TK1 staining (p=0.0003, paired Wilcoxon signed-rank test), and we did not observe a significant inverse correlation between TP_nuc and TK1_nuc (r = −0.17, p=0.08, Spearman's correlation coefficient).

Figure 6

Boxplot of cytoplasmic TP vs CD31. Cytoplasmic TP staining was significantly greater for those with high (>6) compared with low (≤6) Chalkley score for CD31 staining (mean cytoplasmic TP staining, 115.8 vs 79.9, respectively, p<0.001). The length of the box represents the interquartile data range (the distance between the 25th and the 75th percentiles). The plus symbol in the box interior denotes the data mean, and the horizontal line in the box interior represents the data median. Vertical lines extending from the box mark the minimum and maximum observed values.

Ki-67

Increased tumor cell proliferation is a contributing factor to tumor size and metabolic burden, and might be expected to be associated with angiogenesis. However, we found that the Ki-67 labeling index was not significantly associated with the Chalkley score (Table 1, p=0.70, Wilcoxon rank-sum test), TP_cyt staining (r = −0.04, p=0.65; Spearman's correlation coefficient, data not shown), or TP_nuc staining (r = −0.17, p=0.08, Spearman's correlation coefficient).

Tumor Size

Tumors ranged in size from 1.0 to 7.7 cm in diameter (Table 2). Tumor size was not significantly associated with TP_nuc (r = 0.14, p=0.15, Spearman's correlation coefficient), TP_cyt (r = 0.11, p=0.26, Spearman's correlation coefficient), TK1_nuc (r = −0.05, p=0.58, Spearman's correlation coefficient), TK1_cyt (r = 0.03, p=0.79, Spearman's correlation coefficient), Ki-67 labeling index (r = −0.04, p=0.68, Spearman's correlation coefficient), or Chalkley score (p=0.37, Wilcoxon rank-sum test; data not shown).

Discussion

These IHC studies were undertaken to complement our investigations in PET imaging, currently the only clinical tool capable of tracking enzyme activities in vivo in a non-invasive yet quantifiable manner. Over the past several years, we have developed the now widely used PET tracer 3'-deoxy-3'-[F-18]fluorothymidine ([F-18] FLT) to track TK1 activity. However, it would be very useful to also have a PET tracer to monitor thymidine catabolism via TP to better understand the overall disposition of thymidine in tumors and the associated generation of metabolic signals, which can profoundly affect proliferation and angiogenesis.

We tested our composite scoring data for any correlations in the expression of TP relative to that of TK1. TP and TK1 share a common substrate, thymidine, and catalyze opposing reactions. Therefore, we hypothesized that they would demonstrate an inverse relationship with reference to their expression, as has been reported in hematologic malignancies (Shiotani et al. 1989a,b). However, we did not observe substantial positive or negative correlations either between TP_nuc and TK1_nuc expression or between that of TP_cyt and TK1_cyt. In the only other report we have found examining the relationship between TK1 and TP within the same solid tumors, TK1 mRNA expression and TP mRNA expression were both increased in cervical cancer, although comparing their expression in individual samples did not reveal any significant association (Fujiwaki et al. 2001). However, the failure to detect correlations in our data may be due to sampling errors resulting from the well-documented heterogeneity within NSCLC tumors at the light microscopic (Willis 1948; Hirsch et al. 1983), immuno-histochemical (Gatter et al. 1985), electron microscopic (Dunnill and Gatter 1986), and genomic (Petersen and Petersen 2001) levels (Figure 2).

Our study reveals a number of critical associations in NSCLC, among them the strong correlations between nuclear and cytoplasmic staining for TP and, similarly, for TK1. This is an important point in determining the prognostic value of staining in these compartments, particularly in the context of imaging research, because present imaging modalities are unable to discern between nuclear and cytoplasmic signals. The cytoplasmic and nuclear localization of TK1 (Kuroiwa et al. 2001; Cui et al. 2004) and TP (Matsuura et al. 1999; Stavropoulos et al. 2005) is consistent with previous studies. Nuclear TP staining has been reported to be a prognostic indicator of survival in squamous head and neck cancer (Koukourakis et al. 2000), gallbladder adenocarcinoma (Giatromanolaki et al. 2002), and superficial bladder cancer (Stavropoulos et al. 2005). However, in only one of these studies (Koukourakis et al. 2000) was a correlation between the staining in the two compartments evaluated. In the present study, we used the same anti-TP monoclonal antibody (Koukourakis et al. 2000; Giatromanolaki et al. 2002; Stavropoulos et al. 2005) and found a strong correlation between nuclear and cytoplasmic TP staining, making it unlikely that prognostic significance could be associated with staining in one compartment but not the other.

Inasmuch as the end products of both TP and TK1 are small molecules and should easily pass through the nuclear pores, it is not immediately apparent why the enzymes should be translocated into the nucleus. Although experiments to examine this question are beyond the scope of the present study, there is evidence to suggest a critical role for TK1 and TP in the nucleus. The absolute levels and relative proportions of the four dNTPs used in DNA synthesis are tightly regulated. Perturbation of this regulation results in errors of DNA replication, stalling of the replication fork, and increased mutation rates, eventually leading to genetic instability and death (Yoshioka et al. 1987; Hu and Chang 2007). TK1 and enzymes of the de novo thymidine synthesis pathway (thymidylate synthase, dihydrofolate reductase) have been coisolated in a large nuclear multimeric enzyme complex with DNA polymerase α (the “replitase”), which is believed to be associated with the replication fork of mammalian cells only during the S and G₂/M phases (veer Reddy and Pardee 1980, 1983; Noguchi et al. 1983; Plucinski et al. 1990). Because the replication fork is the site where dNTP incorporation must take place with absolute fidelity at very great speed, the replitase complex would seem to ensure localized and rapid response to dNTP demand and proportionality without having to rely on a widely distributed, slower responding equilibration with the cytosolic and mitochondrial pools of dNTPs. Although there have been no reports of TP being associated with the replitase complex, TP may also be present to abrogate local excesses in thymidine concentration that endanger the dNTP balance (Weinberg et al. 1981; Ke et al. 2005; Hu and Chang 2007).

With regard to imaging, TK1 is the enzyme that phosphorylates the PET imaging tracer [F-18]FLT, resulting in its metabolic trapping within the cell, and [F-18]FLT uptake by cells is correlated with their TK1 enzymatic activity (Kong et al. 1992; Rasey et al. 2002). In the present study, we observed a strong correlation between TK1 expression and Ki-67 labeling, which is consistent with our previously reported strong correlation between Ki-67 labeling and standardized uptake value measures of [F-18]FLT uptake in NSCLC tumors (Vesselle et al. 2002).

Recent studies have demonstrated that angiogenesis can proceed by any one of several parallel pathways in several tumor types, including NSCLC (Mizukami et al. 2005; McClelland et al. 2007). In the present case, our data reveal a significant association between TP expression and Chalkley scoring of CD31 staining. Although the tumors used in this study are all at least 1 cm in diameter and therefore too large to contribute information about the initial molecular commitment to angiogenesis, the observed association between TP and Chalkley score is consistent with ongoing maintenance of an already-established angiogenic process in NSCLC.

Finally, we found no correlation between the Ki-67 labeling index and either TP expression or CD31 staining. It might be expected that the percentage of actively dividing cells, reflected by Ki-67 staining, would have a positive correlation with angiogenesis; however, this was not supported in the present study of NSCLC. Hlatky et al. (2002) state that angiogenesis increases not in response to tumor proliferation, but rather to tumor “metabolic burden,” i.e., nutrient and oxygen demands. Many tumors have been shown to tolerate hypoxic conditions much better than corresponding normal tissue (Graeber et al. 1996), which may reflect their lower oxygen consumption rates (Steinberg et al. 1997) due to their reliance on glycolysis to produce ATP (Kim and Dang 2006). Consequently, many tumors have a decreased metabolic burden relative to normal tissue, and provide a reduced angiogenic stimulus. Eberhard et al. (2000) found that in several different solid tumors, the MVD of surrounding normal tissue was usually greater than that of the actively growing tumor; normal lung had a MVD over 3-fold greater than that of angiogenic lung carcinoma, which is consistent with the normal lung's performance of gas exchange. Angiogenesis in NSCLC tumors is further complicated by the fact that the advancing margins of the tumor may opportunistically decrease their metabolic burden by “coopting” existing vessels of the highly vascular adjacent normal lung and air-filled alveolar spaces (Pezzella et al. 1997; Sardari Nia et al. 2008). This suggests that the regulation of angiogenesis as it relates to metabolic burden will need to be individually established for any given tissue or, potentially, even any tumor.

These results provide important insights into the disposition of thymidine as it relates to proliferation and angiogenesis in NSCLC, as well as additional context for the development of PET imaging tracers that we hope will specifically track angiogenic vs proliferative signals in the thymidine salvage pathway. In the case of TK1, IHC detection of expression may not accurately reflect enzyme activity levels, because TK1 enzymatic activity is subject to rigorous posttranslational modification (Sherley and Kelly 1988; Rasey et al. 2002; Ke et al. 2005; Hu and Chang 2007), although this regulation is perturbed in transformed cells (Hengstschlager et al. 1994a,b), possibly as a result of TK1 overexpression (Mikulits et al. 1996). We are currently performing TK1 activity assays on a subset of these tumors, with the goal of determining just how closely our IHC results track TK1 enzyme activity. In contrast, TP activity is not known to be regulated by posttranslational modifications, and we expect TP staining to closely correspond to tumor TP enzymatic activity. We plan to use the results of these studies to facilitate further development of PET imaging tracers targeting TP and tumor angiogenesis in NSCLC (Grierson et al. 2007).

Footnotes

Acknowledgements

This work was supported in part by Grants CA-115559 and CA-107264 from the National Institutes of Health.

References

Aikawa

Takahashi

Fujimura

Sato

Endo

Sakurada

Kondo

(1999) Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer. Anticancer Res, 19:4305–4309.

Brown

Bicknell

(1998) Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J, 334:1–8.

Chalkley

(1943) Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst, 4:47–53.

Chujo

Miura

Kawano

Miyawaki

Imakiire

Hayashita

Kawahara

(2006) Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues. Oncol Rep, 16:777–780.

Cotter

Lennon

Glynn

Martin

(1990) Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res, 10:1153–1159.

Cui

Shi

Zhou

(2004) The changes of gene expression profiles in hydatidiform mole and choriocarcinoma with hyperplasia of trophoblasts. Int J Gynecol Cancer, 14:984–997.

de Bruin

Smid

Laan

Noordhuis

Fukushima

Hoekman

Pinedo

(2003) Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun, 301:675–679.

Dunnill

Gatter

(1986) Cellular heterogeneity in lung cancer. Histopathology, 10:461–475.

Eberhard

Kahlert

Goede

Hemmerlein

Plate

Augustin

(2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res, 60:1388–1393.

10.

Folkman

(2003) Fundamental concepts of the angiogenic process. Curr Mol Med, 3:643–651.

11.

Fox

Leek

Smith

Hollyer

Greenall

Harris

(1994) Tumor angiogenesis in node-negative breast carcinomas: relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat, 29:109–116.

12.

Fox

Leek

Smith

Hollyer

Greenall

Harris

(1995a) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol, 177:275–283.

13.

Fox

Moghaddam

Westwood

Turley

Bicknell

Gatter

Harris

(1995b) Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol, 176:183–190.

14.

Fujiwaki

Hata

Moriyama

Iwanari

Katabuchi

Okamura

Miyazaki

(2001) Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology, 61:47–54.

15.

Gatter

Dunnill

Pulford

Heryet

Mason

(1985) Human lung tumours: a correlation of antigenic profile with histological type. Histopathology, 9:805–823.

16.

Giatromanolaki

Sivridis

Simopoulos

Polychronidis

Gatter

Harris

Koukourakis

(2002) Thymidine phosphorylase expression in gallbladder adenocarcinomas. Int J Surg Pathol, 10:181–188.

17.

Graeber

Osmanian

Jacks

Housman

Koch

Lowe

Giaccia

(1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379:88–91.

18.

Grierson

Brockenbrough

Rasey

Wiens

Schwartz

Jordan

Vesselle

(2007) Evaluation of 5′-deoxy-5′-[F-18] fluorothymidine as a tracer of intracellular thymidine phosphorylase activity. Nucl Med Biol, 34:471–478.

19.

Grierson

Shields

(2000) Radiosynthesis of 3′-deoxy-3′-[(18) F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol, 27:143–156.

20.

Haraguchi

Miyadera

Uemura

Sumizawa

Furukawa

Yamada

Akiyama

(1994) Angiogenic activity of enzymes. Nature, 368:198.

21.

Hengstschlager

Knofler

Mullner

Ogris

Wintersberger

Wawra

(1994a) Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem, 269:13836–13842.

22.

Hengstschlager

Mudrak

Wintersberger

Wawra

(1994b) A common regulation of genes encoding enzymes of the deoxy-nucleotide metabolism is lost after neoplastic transformation. Cell Growth Differ, 5:1389–1394.

23.

Hirano

Takayama

Kageyama

Ushiyama

Suzuki

Fujita

(2003) Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil. Eur Urol, 43:45–51.

24.

Hirsch

Ottesen

Pødenphant

Olsen

(1983) Tumor heterogeneity in lung cancer based on light microscopic features. A retrospective study of a consecutive series of 200 patients, treated surgically. Virchows Arch A Pathol Anat Histopathol, 402:147–153.

25.

Hlatky

Hahnfeldt

Folkman

(2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst, 94:883–893.

26.

Hotchkiss

Ashton

Klein

Lenzi

Zhu

Schwartz

(2003) Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res, 63:527–533.

27.

Chang

(2007) Mitotic control of dTTP pool: a necessity or coincidence?. J Biomed Sci, 14:491–497.

28.

Ikeda

Che

Ushiyama

Yamaguchi

Okumura

Nakajima

Takeda

(2006) 2-Deoxy-D-ribose inhibits hypoxia-induced apoptosis by suppressing the phosphorylation of p38 MAPK. Biochem Biophys Res Commun, 342:280–285.

29.

Ikeda

Furukawa

Kitazono

Ishitsuka

Okumura

Tani

Sumizawa

(2002) Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-ribose. Biochem Biophys Res Commun, 291:806–812.

30.

Ikeguchi

Oka

Saito

Kondo

Tsujitani

Maeta

Kaibara

(1999) Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas. Eur Surg Res, 31:357–363.

31.

Johansson

Brismar

Karlsson

(1997) Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA, 94:11941–11945.

32.

Kuo

Chang

(2005) Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. Genes Dev, 19:1920–1933.

33.

Key

Becker

Baron

Duchrow

Schlüter

Flad

Gerdes

(1993) New Ki-67-equivalent murine monoclonal antibodies (MIB 1–3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest, 68:629–636.

34.

Kim

Dang

(2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res, 66:8927–8930.

35.

Klecker

Jr Collins

(2001) Thymidine phosphorylase as a target for imaging and therapy with thymine analogs. Cancer Chemother Pharmacol, 48:407–412.

36.

Koide

Watanabe

Yazawa

Adachi

Amano

(1999) Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology, 46:944–951.

37.

Kong

Zhu

Vidal

Watanabe

Polsky

Armstrong

Ostrander

(1992) Comparisons of anti-human immuno-deficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother, 36:808–818.

38.

Koukourakis

Giatromanolaki

Fountzilas

Sivridis

Gatter

Harris

(2000) Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res, 6:381–389.

39.

Koukourakis

Giatromanolaki

Kakolyris

O'Byrne

Apostolikas

Skarlatos

Gatter

(1998) Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer, 77:1696–1703.

40.

Koukourakis

Giatromanolaki

O'Byrne

Comley

Whitehouse

Talbot

Gatter

(1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer, 75:477–481.

41.

Kuroiwa

Nakayama

Fukuda

Fukui

Ohwada

Hiwasa

Fujimura

(2001) Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J Immunol Methods, 253:1–11.

42.

Landry

Freyer

Sutherland

(1981) Shedding of mitotic cells from the surface of multicell spheroids during growth. J Cell Physiol, 106:23–32.

43.

Shintani

Terakado

Klosek

Ishikawa

Nakashiro

Hamakawa

(2005) Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg, 34:559–565.

44.

Liekens

Bronckaers

Pérez-Pérez

Balzarini

(2007) Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol, 74:1555–1567.

45.

Maehara

Moriguchi

Emi

Watanabe

Kohnoe

Tsujitani

Sugimachi

(1990) Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas. Cancer, 66:156–161.

46.

Mao

Skog

Eriksson

Zhao

Zhou

(2005) Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep, 13:837–846.

47.

Mao

Wang

Skog

(2002) A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest, 20:922–931.

48.

Matsuura

Kuratate

Teramachi

Osaki

Fukuda

Ito

(1999) Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res, 59:5037–5040.

49.

McClelland

Carskadon

Zhao

White

Beer

Orringer

Pickens

(2007) Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol, 36:343–350.

50.

Mikulits

Hengstschläger

Sauer

Wintersberger

Müllner

(1996) Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem, 271:853–860.

51.

Miyake

Imura

Yoshizumi

Ikemoto

Morine

Shimada

(2007) Role of thymidine phosphorylase and orotate phospho-ribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol, 12:111–119.

52.

Mizukami

Duerr

Gala

Zhang

Zimmer

(2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med, 11:992–997.

53.

Moghaddam

Zhang

Fan

Lees

Turley

Fox

(1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA, 92:998–1002.

54.

Morita

Matsuzaki

Tokue

(2003) Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology, 65:125–131.

55.

Noguchi

Prem veer Reddy

Pardee

(1983) Rapid incorporation of label from ribonucleoside disphosphates into DNA by a cell-free high molecular weight fraction from animal cell nuclei. Cell, 32:443–451.

56.

O'Brien

Cranston

Fuggle

Bicknell

Harris

(1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res, 55:510–513.

57.

O'Brien

Fox

Dickinson

Turley

Westwood

Moghaddam

Gatter

(1996) Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res, 56:4799–4804.

58.

O'Byrne

Koukourakis

Giatromanolaki

Cox

Turley

Steward

Gatter

(2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer, 82:1427–1432.

59.

Oudard

Levalois

Andrieu

Bougaran

Validire

Thiounn

Poupon

(2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res, 22:121–128.

60.

Overholtzer

Mailleux

Mouneimne

Normand

Schnitt

King

Cibas

(2007) A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell, 131:966–979.

61.

Parums

Cordell

Micklem

Heryet

Gatter

Mason

(1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol, 43:752–757.

62.

Passantino

Patruno

Valerio

Penna

Mazzone

Zito

Catalano

(2005) Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol, 27:95–107.

63.

Petersen

(2001) Towards a genetic-based classification of human lung cancer. Anal Cell Pathol, 22:111–121.

64.

Pezzella

Pastorino

Tagliabue

Andreola

Sozzi

Gasparini

Menard

(1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol, 151:1417–1423.

65.

Plucinski

Fager

Reddy

(1990) Allosteric interaction of components of the replitase complex is responsible for enzyme cross-inhibition. Mol Pharmacol, 38:114–120.

66.

Rasey

Grierson

Wiens

Kolb

Schwartz

(2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med, 43:1210–1217.

67.

Sardari Nia

Colpaert

Vermeulen

Weyler

Pezzella

Van Schil

Van Marck

(2008) Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes. Ann Thorac Surg, 85:395–405.

68.

Sato

Sata

Nakamura

Inoue

Wada

Takabatake

Otake

(2003) Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer, 106:863–870.

69.

Sherley

Kelly

(1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem, 263:8350–8358.

70.

Shields

Grierson

Dohmen

Machulla

Stayanoff

Lawhorn-Crews

Obradovich

(1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 4:1334–1336.

71.

Shiotani

Hashimoto

Fujita

Yamauchi

Yamaji

Futami

Bungo

(1989a) Reversal of enzymic phenotype of thymidine metabolism in induced differentiation of U-937 cells. Cancer Res, 49:6758–6763.

72.

Shiotani

Hashimoto

Tanaka

Irino

(1989b) Behavior of activities of thymidine metabolizing enzymes in human leukemia-lymphoma cells. Cancer Res, 49:1090–1094.

73.

Stavropoulos

Bouropoulos

Ioachim

Michael

Hastazeris

Tsimaris

Kalogeras

(2005) Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma. Int Urol Nephrol, 37:55–60.

74.

Steinberg

Röhrborn

Otto

Scheufler

Streffer

(1997) NIR reflection measurements of hemoglobin and cytochrome aa3 in healthy tissue and tumors. Correlations to oxygen consumption: preclinical and clinical data. Adv Exp Med Biol, 428:69–77.

75.

Takebayashi

Akiyama

Akiba

Yamada

Miyadera

Sumizawa

Yamada

(1996a) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst, 88:1110–1117.

76.

Takebayashi

Yamada

Miyadera

Sumizawa

Furukawa

Kinoshita

Aoki

(1996b) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227–1232.

77.

Prajapati

Park

Kelly

Yamamoto

Gaynor

(2006) IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J Biol Chem, 281:6699–6706.

78.

Uchimiya

Furukawa

Okamoto

Nakajima

Matsushita

Ikeda

Gotanda

(2002) Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res, 62:2834–2839.

79.

veer Reddy

Pardee

(1980) Multienzyme complex for metabolic channeling in mammalian DNA replication. Proc Natl Acad Sci USA, 77:3312–3316.

80.

veer Reddy

Pardee

(1983) Inhibitor evidence for allosteric interaction in the replitase multienzyme complex. Nature, 304: 86–88.

81.

Vertongen

Fondu

van den Heule

Cauchie

Mandelbaum

(1984) Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma. Tumour Biol, 5:303–311.

82.

Vesselle

Freeman

Wiens

Stern

Nguyen

Hawes

Bastian

(2007) Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res, 13:255–263.

83.

Vesselle

Grierson

Muzi

Pugsley

Schmidt

Rabinowitz

Peterson

(2002) In vivo validation of 3′deoxy-3′-[(18)F] fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res, 8:3315–3323.

84.

Vesselle

Turcotte

Wiens

Schmidt

Takasugi

Lalani

Vallières

(2004) Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res, 10:4709–4716.

85.

Volm

Mattern

Koomagi

(1998) Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int J Oncol, 13:975–979.

86.

Weinberg

Ullman

Martin

Jr (1981) Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools. Proc Natl Acad Sci USA, 78:2447–2451.

87.

Willis

(1948) Epithelial tumours of the trachea, bronchi and lung. In Pathology of Tumors. Butterworth, London.

88.

Mao

Wang

Skog

(2000) A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res, 20:4815–4820.

89.

Yasuno

Mori

Koike

Takahashi

Toi

Takizawa

Shimizu

(2005) Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep, 13:405–412.

90.

Yoshioka

Tanaka

Hiraoka

Koyama

Hirota

Ayusawa

Seno

(1987) Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem, 262:8235–8241.

91.

Yusa

Yamaguchi

Ohwada

Hayashi

Kuroiwa

Morita

Asanagi

(1988) Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy. Cancer Res, 48:5001–5006.

Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation

Abstract

Keywords

Materials and Methods

Patient Population and Tumor Type

Immunohistochemistry

Statistical Analysis

Results

Nuclear TP vs Cytoplasmic TP

Nuclear TK1 vs Cytoplasmic TK1

Relationship Between TK1 Staining and Ki-67 Labeling Index

Relationship Between TP Staining and Chalkley Score

TK1 Staining vs TP Staining

Ki-67

Tumor Size

Discussion

Footnotes

Acknowledgements

References